

Mark G Lebowhl

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4648314/mark-g-lebwohl-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

373
papers

24,695
citations

81
h-index

151
g-index

392
ext. papers

28,757
ext. citations

5.5
avg, IF

7.06
L-index

#	Paper	IF	Citations
373	Secukinumab in plaque psoriasis--results of two phase 3 trials. <i>New England Journal of Medicine</i> , 2014 , 371, 326-38	59.2	1319
372	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). <i>Lancet, The</i> , 2008 , 371, 1675-84	40	1150
371	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 826-50	4.5	958
370	A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. <i>New England Journal of Medicine</i> , 2007 , 356, 580-92	59.2	644
369	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , 2015 , 386, 541-51	40	576
368	The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. <i>Archives of Dermatology</i> , 2001 , 137, 280-4		564
367	Psoriasis. <i>Lancet, The</i> , 2003 , 361, 1197-204	40	558
366	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015 , 373, 1318-28	59.2	530
365	A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. <i>New England Journal of Medicine</i> , 2003 , 349, 2004-13	59.2	502
364	CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. <i>Journal of Clinical Investigation</i> , 1999 , 103, 1243-52	15.9	463
363	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 451-85	4.5	427
362	Ingenol mebutate gel for actinic keratosis. <i>New England Journal of Medicine</i> , 2012 , 366, 1010-9	59.2	379
361	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 851-64	4.5	349
360	Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 643-59	4.5	344
359	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 137-74	4.5	343
358	Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 871-81.e1-30	4.5	332
357	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 1031-42	4.5	329

356	Psoriasis. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16082	51.1	327
355	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1029-1072	4.5	296
354	Methotrexate in psoriasis: consensus conference. <i>Journal of the American Academy of Dermatology</i> , 1998 , 38, 478-85	4.5	288
353	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 494-503.e6	4.5	286
352	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>British Journal of Dermatology</i> , 2013 , 168, 844-54	4	284
351	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018 , 392, 650-661	4.0	283
350	Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. <i>Journal of the American Academy of Dermatology</i> , 2001 , 44, 534-7	4.5	278
349	Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. <i>Journal of Experimental Medicine</i> , 2000 , 192, 681-94	16.6	273
348	An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. <i>Archives of Dermatology</i> , 2003 , 139, 719-27		271
347	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 114-135	4.5	267
346	Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>JAMA Dermatology</i> , 2015 , 151, 961-9	5.1	247
345	Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. <i>JAMA Dermatology</i> , 2013 , 149, 1180-5	5.1	238
344	Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 714-21	4.5	235
343	Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 824-37	4.5	233
342	Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 27-40	4.5	177
341	Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2000 , 42, 428-35	4.5	175
340	Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, 281-5	4.5	174
339	Treatment of psoriasis. Part 1. Topical therapy and phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2001 , 45, 487-98; quiz 499-502	4.5	174

338	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 872-881.e6	4.5	172
337	The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 34, 819-36	5.3	171
336	Treatments for psoriasis and the risk of malignancy. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 1001-17	4.5	166
335	Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1998 , 39, 464-75	4.5	163
334	Treatment of psoriasis. Part 2. Systemic therapies. <i>Journal of the American Academy of Dermatology</i> , 2001 , 45, 649-61; quiz 662-4	4.5	158
333	Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 43-53	4.5	149
332	Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. <i>British Journal of Dermatology</i> , 2015 , 172, 1371-83	4	147
331	Afamelanotide for Erythropoietic Protoporphyrria. <i>New England Journal of Medicine</i> , 2015 , 373, 48-59	59.2	145
330	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1073-1113	4.5	145
329	Combination therapy to treat moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 416-30	4.5	142
328	Classification of pseudoxanthoma elasticum: report of a consensus conference. <i>Journal of the American Academy of Dermatology</i> , 1994 , 30, 103-7	4.5	140
327	Tacrolimus ointment is effective for facial and intertriginous psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, 723-30	4.5	139
326	Duration of remission of psoriasis therapies. <i>Journal of the American Academy of Dermatology</i> , 1999 , 41, 51-9	4.5	138
325	Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH2 skewing. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 1277-87	11.5	132
324	A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1996 , 35, 268-9	4.5	123
323	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 87-97	7.1	121
322	Pseudoxanthoma elasticum and mitral-valve prolapse. <i>New England Journal of Medicine</i> , 1982 , 307, 228-31	39.2	118
321	Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. <i>JAMA Dermatology</i> , 2013 , 149, 666-70	5.1	116

320	From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 168-77	4.5	107
319	Collagen alterations in chronically sun-damaged human skin. <i>Photochemistry and Photobiology</i> , 1993 , 58, 841-4	3.6	107
318	Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1998 , 39, 590-6	4.5	106
317	The effect of weight on the efficacy of biologic therapy in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 443-6	4.5	104
316	Association of patient-reported psoriasis severity with income and employment. <i>Journal of the American Academy of Dermatology</i> , 2007 , 57, 963-71	4.5	104
315	Relapse, rebound, and psoriasis adverse events: an advisory group report. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S171-81	4.5	104
314	Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. <i>Journal of the American Academy of Dermatology</i> , 2007 , 57, 957-62	4.5	102
313	Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2001 , 45, 544-53	4.5	100
312	Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. <i>JAMA Dermatology</i> , 2015 , 151, 42-50	5.1	97
311	Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, 731-8	4.5	96
310	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 81-89.e5	4.5	95
309	Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. <i>Journal of the American Academy of Dermatology</i> , 2003 , 48, 760-7	4.5	95
308	Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 845-854.e5	4.5	93
307	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. <i>British Journal of Dermatology</i> , 2011 , 164, 862-72	4	93
306	Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. <i>Experimental Dermatology</i> , 2018 , 27, 409-417	4	92
305	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 571-9	4.5	92
304	Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. <i>Journal of the American Academy of Dermatology</i> , 1998 , 39, 447-50	4.5	92
303	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 290-298	4.5	90

302	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 432-440.e175	4.5	88
301	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1176-82	4.5	87
300	From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 94-105	4.5	87
299	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 266-276.e5	4.5	86
298	Therapy for head lice based on life cycle, resistance, and safety considerations. <i>Pediatrics</i> , 2007 , 119, 965-74	7.4	86
297	Research gaps in psoriasis: opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 146-67	4.5	85
296	A clinician's paradigm in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2005 , 53, S59-69	4.5	85
295	Brief report: occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. <i>New England Journal of Medicine</i> , 1993 , 329, 1237-9	59.2	85
294	Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017 , 5, 1519-1531	5.4	82
293	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 731-41	4.5	82
292	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 142-154	11.5	80
291	Evaluating the economic burden of psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 961-7.e5	4.5	79
290	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1445-1486	4.5	79
289	Actinic keratosis: epidemiology and progression to squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2003 , 149 Suppl 66, 31-3	4	79
288	Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. <i>British Journal of Dermatology</i> , 2010 , 162, 137-46	4	76
287	Compatibility of calcipotriene with other topical medications. <i>Journal of the American Academy of Dermatology</i> , 1998 , 38, 1010-1	4.5	76
286	Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 962-71	4.5	73
285	Interactions between calcipotriene and ultraviolet light. <i>Journal of the American Academy of Dermatology</i> , 1997 , 37, 93-5	4.5	73

284	Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1998 , 38, 705-11	4.5	72
283	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. <i>JAMA Dermatology</i> , 2018 , 154, 934-950	5.1	70
282	Psoriasis treatment: traditional therapy. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii83-6	2.4	65
281	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 77-82.e7	4.5	65
280	Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 838-53	4.5	63
279	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 161-201	4.5	63
278	The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 667-674	4.5	62
277	Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 553-6	4.5	62
276	Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2020 , 396, 110-120	4.0	59
275	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 851-61.e4	4.5	59
274	Acitretin in combination with UVB or PUVA. <i>Journal of the American Academy of Dermatology</i> , 1999 , 41, S22-4	4.5	57
273	Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 469-71	4.5	55
272	A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 733-740.e11	4.5	55
271	Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , 2017 , 153, 698-704	5.1	54
270	Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 537-545	4.5	53
269	Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 120-4	4.5	53
268	Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 363-375	7.1	51
267	Psoriasis and the metabolic syndrome. <i>Dermatologic Therapy</i> , 2010 , 23, 137-43	2.2	51

266	A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure. <i>Journal of Molecular Medicine</i> , 2000 , 78, 36-46	5.5	51
265	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 487-498	4.0	51
264	An update on generalized pustular psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 907-919	5.1	50
263	IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 1946-1953	4.3	50
262	From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 178-86	4.5	50
261	Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. <i>Journal of Drugs in Dermatology</i> , 2016 , 15, 390-6	2.2	50
260	Combining the new biologic agents with our current psoriasis armamentarium. <i>Journal of the American Academy of Dermatology</i> , 2003 , 49, S118-24	4.5	49
259	Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 301-304	11.5	48
258	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 323-332	4.5	47
257	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 775-804	4.5	47
256	Review of safety and efficacy of approved systemic psoriasis therapies. <i>International Journal of Dermatology</i> , 2019 , 58, 649-658	1.7	47
255	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 432-470	4.5	46
254	Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. <i>Journal of Immunology</i> , 2017 , 198, 3809-3814	5.3	45
253	Herpes zoster in psoriasis patients treated with tofacitinib. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 302-309	4.5	45
252	Combining systemic retinoids with biologic agents for moderate to severe psoriasis. <i>International Journal of Dermatology</i> , 2008 , 47, 514-8	1.7	45
251	The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 61-3	4.5	44
250	Abnormalities of connective tissue components in lesional and non-lesional tissue of patients with pseudoxanthoma elasticum. <i>Archives of Dermatological Research</i> , 1993 , 285, 121-6	3.3	44
249	The use of systemic immune moderators in dermatology: an update. <i>Dermatologic Clinics</i> , 2005 , 23, 259-300	3.0	43

248	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 2202-2211	4.3	42
247	Topical corticosteroids in psoriasis: strategies for improving safety. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 119-24	4.6	42
246	Topical calcipotriene in combination with UVB phototherapy for psoriasis. <i>International Journal of Dermatology</i> , 1997 , 36, 302-3	1.7	42
245	An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2005 , 53, 73-5	4.5	42
244	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1254-1268	4.5	42
243	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 383-394	4.5	41
242	A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 637-41	4.5	41
241	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. <i>International Journal of Dermatology</i> , 2002 , 41, 269-74	1.7	41
240	No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. <i>Archives of Dermatology</i> , 2005 , 141, 861-4		41
239	Phototherapy in dermatology: A call for action. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 1078-80	4.5	39
238	Interactions between tazarotene and ultraviolet light. <i>Journal of the American Academy of Dermatology</i> , 1999 , 41, 927-30	4.5	39
237	Oral phosphate binders in the treatment of pseudoxanthoma elasticum. <i>Journal of the American Academy of Dermatology</i> , 2005 , 53, 610-5	4.5	38
236	Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). <i>Dermatology and Therapy</i> , 2018 , 8, 571-579	4	38
235	Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. <i>Journal of the American Academy of Dermatology</i> , 2001 , 44, 77-82	4.5	37
234	Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>Journal of Dermatological Treatment</i> , 2017 , 28, 282-287	2.8	35
233	Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 352-359	4.5	35
232	Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype. <i>Pediatric Dermatology</i> , 2000 , 17, 12-20	1.9	34
231	Biologics and Psoriasis: The Beat Goes On. <i>Dermatologic Clinics</i> , 2019 , 37, 29-36	4.2	34

230	Impaired skin barrier function in dermatologic disease and repair with moisturization. <i>Cutis</i> , 2005 , 76, 7-12	0.4	34
229	Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. <i>International Journal of Dermatology</i> , 2004 , 43 Suppl 1, 17-20	1.7	33
228	Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. <i>International Journal of Dermatology</i> , 2001 , 40, 64-6	1.7	33
227	Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015 , 8, 14-20	1.2	33
226	Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 372-374	4.5	32
225	Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 287-293	4.5	31
224	Psoriasis. <i>Annals of Internal Medicine</i> , 2018 , 168, ITC49-ITC64	8	31
223	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
222	Biologics in combination with nonbiologics: efficacy and safety. <i>Dermatologic Therapy</i> , 2004 , 17, 432-40	2.2	30
221	Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. <i>Journal of Drugs in Dermatology</i> , 2017 , 16, 801-808	2.2	30
220	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020 , 10, 133-150	4	29
219	Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 857-859	4.5	27
218	Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. <i>International Journal of Dermatology</i> , 2016 , 55, 401-7	1.7	27
217	Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, S43-6	4.5	26
216	Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 127-33	4.5	25
215	Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 525-32	4.5	24
214	Proven efficacy of tacrolimus for facial and intertriginous psoriasis. <i>Archives of Dermatology</i> , 2005 , 141, 1154		24
213	Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 2095-2107	11.5	24

212	Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. <i>Clinical Therapeutics</i> , 2017 , 39, 849-862.e6	3.5	23
211	A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 341-348	4.5	23
210	A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. <i>International Journal of Dermatology</i> , 1999 , 38, 604-6	1.7	23
209	Topical therapy for psoriasis. <i>International Journal of Dermatology</i> , 1995 , 34, 673-84	1.7	23
208	Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1314-1320	4.5	23
207	A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. <i>Archives of Dermatological Research</i> , 2019 , 311, 29-36	3.3	23
206	Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 221-228	2.2	23
205	Itch: an under-recognized problem in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1465-1476	4.6	22
204	Acitretin suppression of squamous cell carcinoma: case report and literature review. <i>Journal of Dermatological Treatment</i> , 2003 , 14 Suppl 2, 3-6	2.8	22
203	Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 303-312	1.6	22
202	Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 546-552	4.6	22
201	Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 59-62	4.5	21
200	Case studies in severe psoriasis: A clinical strategy. <i>Journal of Dermatological Treatment</i> , 2003 , 14 Suppl 2, 26-46	2.8	20
199	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 863-871	7.1	19
198	Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 885-892	4.6	19
197	A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 385-92	4.5	19
196	Obesity, smoking, and psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 208-10	27.4	19
195	Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. <i>Skinmed</i> , 2017 , 15, 119-124	0.2	19

194	Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 96-103	4.5	18
193	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 741-748	4.5	18
192	Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient. <i>International Journal of Dermatology</i> , 1997 , 36, 205-7	1.7	18
191	Topical calcitriol is degraded by ultraviolet light. <i>Journal of Investigative Dermatology</i> , 2003 , 121, 594-5	4.3	18
190	Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. <i>Dermatology</i> , 2005 , 211, 256-63	4.4	18
189	TNF inhibitors for psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018 , 37, 134-142	1.4	18
188	Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 360-365	4.5	18
187	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1269-1277	4.5	18
186	Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. <i>BMJ Open</i> , 2019 , 9, e027535	3	17
185	Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2018 , 9, 34-41	1.2	17
184	Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 63-70	4.5	17
183	Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. <i>BMJ Open</i> , 2021 , 11, e043666	3	17
182	Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. <i>Journal of Drugs in Dermatology</i> , 2007 , 6, 428-35	2.2	17
181	Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. <i>Cutis</i> , 2015 , 95, 173-8	0.4	17
180	A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2017 , 16, 197-204	2.2	17
179	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017 , 18, 405-411	7.1	16
178	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 294-301.e6	4.5	16
177	Patient-reported impact of chronic urticaria compared with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2017 , 28, 229-236	2.8	16

176	Topical application of calcipotriene and corticosteroids: combination regimens. <i>Journal of the American Academy of Dermatology</i> , 1997 , 37, S55-8	4.5	16
175	Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. <i>F1000Research</i> , 2017 , 6, 1712	3.6	15
174	The state and consequences of dermatology drug prices in the United States. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 603-605	4.5	15
173	Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 135-142	4.6	15
172	Potential complications associated with the use of biologic agents for psoriasis. <i>Dermatologic Clinics</i> , 2007 , 25, 207-13, vii	4.2	14
171	Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 282-285	4.5	14
170	US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 333-341	2.8	14
169	Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. <i>Cutis</i> , 2009 , 83, 205-12	0.4	14
168	Cutaneous manifestations of inflammatory bowel disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2000 , 14, 349-50	4.6	13
167	Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy. <i>International Journal of Dermatology</i> , 1993 , 32, 830-1	1.7	13
166	Efficacy and safety of ustekinumab in adolescents. <i>Pediatric Health, Medicine and Therapeutics</i> , 2016 , 7, 109-120	2.5	13
165	Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. <i>International Journal of Dermatology</i> , 2016 , 55, e147-55	1.7	13
164	Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 709-717	4.6	13
163	Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of Dermatological Treatment</i> , 2019 , 30, 534-539 ^{2.8}	2.8	13
162	Immunogenicity and skin clearance recapture in clinical studies of brodalumab. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 344-351	4.5	13
161	Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 115-121	4	12
160	What's New in Psoriasis. <i>Dermatologic Clinics</i> , 2019 , 37, 129-136	4.2	12
159	Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 879-886	7.1	12

158	Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. <i>Cutis</i> , 1996 , 57, 62-8	0.4	12
157	Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 711-723	7.1	11
156	Use of etanercept in the dermatology setting. A review. <i>American Journal of Clinical Dermatology</i> , 2005 , 6, 49-59	7.1	11
155	Genital Lentigines in a 6-Year-Old Boy with a Family History of Cowden's Disease: Clinical and Genetic Evidence of the Linkage Between Bannayan-Riley-Ruvacalba Syndrome and Cowden's Disease. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001 , 5, 228-230	1.6	11
154	Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema. <i>International Journal of Dermatology</i> , 2016 , 55, e447-53	1.7	11
153	Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. <i>Cutis</i> , 2001 , 67, 261-6	0.4	11
152	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 360-368	4.5	10
151	Does Treatment of Psoriasis Reduce Cardiovascular Comorbidities?. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1612-1613	4.3	10
150	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. <i>British Journal of Dermatology</i> , 2021 , 185, 935-944	4	10
149	Phase 2a randomized clinical trial of dupilumab (anti-IL-4R α) for alopecia areata patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 ,	9.3	10
148	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1867-1875	4.6	9
147	Magnesium supplementation in the treatment of pseudoxanthoma elasticum: A randomized trial. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 263-265	4.5	9
146	Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1744-1749	4.6	9
145	An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 954-959.e1	4.5	9
144	Cutaneous manifestations of cardiovascular diseases. <i>Clinics in Dermatology</i> , 2008 , 26, 243-54	3	9
143	Interferon and condylomata acuminata. <i>International Journal of Dermatology</i> , 1990 , 29, 699-705	1.7	9
142	The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020 , 13, 44-48	1.2	9
141	Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 519-522	4.5	9

140	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021 , 184, 640-651	4	9
139	The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic options. <i>Cutis</i> , 2010 , 86, suppl 1-11; quiz suppl 12	0.4	9
138	Adherence to topical therapies in actinic keratosis: A literature review. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 538-545	2.8	8
137	Complications of the smallpox vaccine. <i>International Journal of Dermatology</i> , 2005 , 44, 289-92	1.7	8
136	Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	8
135	New roles for systemic retinoids. <i>Journal of Drugs in Dermatology</i> , 2006 , 5, 406-9	2.2	8
134	Biopsy techniques: shave, punch, or excision?. <i>JAMA Dermatology</i> , 2014 , 150, 12-3	5.1	7
133	Ingenol mebutate (ingenol 3-angelate, PEP005): focus on its uses in the treatment of nonmelanoma skin cancer. <i>Expert Review of Dermatology</i> , 2012 , 7, 121-128		7
132	Alefacept: where it stands today. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 355-61	5.5	7
131	Psoriasis: Overview and Diagnosis. <i>Updates in Clinical Dermatology</i> , 2018 , 1-16	0.2	7
130	Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. <i>Dermatology and Therapy</i> , 2021 , 11, 529-544†		7
129	Melkersson-Rosenthal syndrome successfully treated with adalimumab. <i>Cutis</i> , 2018 , 101, 122-124	0.4	7
128	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017 , 177, 587-590	4	6
127	Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 421-430	7.1	6
126	Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, e57-e59	4.5	6
125	Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Psoriasis Forum</i> , 2011 , 17a, 88-96		6
124	Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2003 , 14, 7-16	2.8	6
123	Two-Year US Pharmacovigilance Report on Brodalumab. <i>Dermatology and Therapy</i> , 2021 , 11, 173-180	4	6

122	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. <i>Dermatology and Therapy</i> , 2021 , 11, 221-233	4	6
121	The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis. <i>Cutis</i> , 2007 , 80, 29-40	0.4	6
120	Risk of skin disorders in patients with celiac disease: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1456-1464	4.5	5
119	The Combination of Benzo[a]pyrene and Ultraviolet A Causes an In Vivo Time-related Accumulation of DNA Damage in Mouse Skin. <i>Photochemistry and Photobiology</i> , 2007 , 77, 413-419	3.6	5
118	Innovations in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, S40-1	4.5	5
117	Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	5
116	Ustekinumab as therapy for psoriasis in a 2-year-old girl. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, e109-e110	4.6	5
115	Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1152-1160	4.6	5
114	Three-year U.S. pharmacovigilance report of brodalumab. <i>Dermatologic Therapy</i> , 2021 , 34, e15105	2.2	5
113	Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 1280-1287	2.2	5
112	Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 2082-2086	4.6	4
111	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2020 , 182, 67-75	4	4
110	No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1436-1439	4.5	4
109	Acanthosis nigricans in a plaque of scleredema on the back of a diabetic patient: a case report. <i>International Journal of Dermatology</i> , 2005 , 44, 45-7	1.7	4
108	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.. <i>Acta Dermato-Venereologica</i> , 2022 ,	2.2	4
107	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2021 ,	4	4
106	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2020 , 1-9	2.8	4
105	Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2016 , 9, 211-6	2.9	4

104	Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35 Suppl 1, 35-41	4.6	4
103	Clinically significant therapeutic interactions for the practicing dermatologist. <i>Advances in Dermatology</i> , 1999 , 14, 1-26; discussion 27		4
102	Indications and limitations of afamelanotide for treating vitiligo-reply. <i>JAMA Dermatology</i> , 2015 , 151, 350	5.1	3
101	Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology?. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 2339-2340	4.3	3
100	Review of Available and Investigational Biologics and Non-Biologic Small Molecules for the Treatment of Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 2, 11-21	1.1	3
99	Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 544-51	4.5	3
98	Interleukin-23 blockade: another breakthrough in the treatment of psoriasis. <i>Lancet, The</i> , 2019 , 394, 544-546	4.0	3
97	Secukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 59-61	1.1	3
96	FRI0123 Clinical Outcomes Associated with Switching or Discontinuation of Anti-TNF Inhibitors for Non-Medical Reasons. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 465.1-465	2.4	3
95	Do we need more psoriasis therapies?. <i>Lancet, The</i> , 2015 , 386, 512-4	4.0	3
94	Treatment of Refractory Psoriasis with Ustekinumab in an HIV-Positive Patient: A Case Presentation and Review of the Biologic Literature. <i>Psoriasis Forum</i> , 2014 , 20a, 96-102		3
93	Iatrogenic effects of biologics for psoriasis. <i>Clinics in Dermatology</i> , 2011 , 29, 614-21	3	3
92	Biologic Therapy and the Risk of Malignancy in Psoriasis. <i>Psoriasis Forum</i> , 2011 , 17a, 238-253		3
91	Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 1505-13	5.4	3
90	Actinic Keratosis. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1394-5	27.4	3
89	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. <i>Dermatology</i> , 2021 , 237, 46-55	4.4	3
88	Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 398-407	4.5	3
87	Clinical efficacy and safety of tazarotene: optimizing clinical results. <i>Cutis</i> , 1998 , 61, 27-9	0.4	3

86	Clinical management of psoriasis: principles and practice. <i>Cutis</i> , 2001 , 67, 1-15	0.4	3
85	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.. <i>Dermatology and Therapy</i> , 2022 , 12, 727	4	3
84	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 133-142	1.1	2
83	Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors". <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 744	4.5	2
82	Burden of Psoriasis as Reported in a Cross-Sectional Study: Association of Psoriasis Severity with Health-Related Quality of Life, Depression, and Work Productivity. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 106-112	1.1	2
81	Patient Perspectives on Psoriasis Management: U.S. Results of the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Psoriasis Forum</i> , 2014 , 20a, 124-131		2
80	Do we need a patient satisfaction score?. <i>British Journal of Dermatology</i> , 2014 , 170, 494-5	4	2
79	Review of therapy of psoriasis: the prebiologic armamentarium. <i>Dermatologic Clinics</i> , 2004 , 22, 379-88, viii	4.2	2
78	The disease burden of generalized pustular psoriasis: Real-world evidence from CorEvidas[Psoriasis Registry. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 247553032210798	1.1	2
77	COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 ,	5.4	2
76	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. <i>Advances in Therapy</i> , 2020 , 37, 4730-4753	4.1	2
75	A Preliminary F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 3500-3506	5.4	2
74	Newer Therapies in Psoriasis. <i>Medical Clinics of North America</i> , 2021 , 105, 627-641	7	2
73	Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.. <i>Dermatology and Therapy</i> , 2021 , 12, 407	4	2
72	Comment on "Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis". <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, e377	4.5	1
71	Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 73-80	1.1	1
70	Reply to: "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials". <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, e75	4.5	1
69	Reply to 'complementary data for long-term infliximab use in psoriasis'. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 591-2	4.5	1

68	Frequency of Monotherapy versus Combination Therapy in Reported Cases of Infections Occurring in the Setting of Biologic Agents. <i>Psoriasis Forum</i> , 2013 , 19a, 2-15		1
67	Tumour necrosis factor- β blockers in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2010 , 162, 1169-71	4	1
66	Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings. <i>Psoriasis Forum</i> , 2008 , 14a, 27-34		1
65	Classification of Psoriasis by its Natural History: A New Perspective From Abroad. <i>Psoriasis Forum</i> , 2003 , 9a, 10-11		1
64	Genital lentiginos in a 6-year-old boy with a family history of Cowden's disease: clinical and genetic evidence of the linkage between Bannayan-Riley-Ruvacalba syndrome and Cowden's disease. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001 , 5, 228-30	1.6	1
63	Differential diagnosis of pigmented lesions of the skin. <i>Mount Sinai Journal of Medicine</i> , 1992 , 59, 194-7		1
62	Apremilast and systemic retinoid combination treatment for moderate to severe palmoplantar psoriasis. <i>Cutis</i> , 2020 , 106, E15-E17	0.4	1
61	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2011 , 4, 28-39	1.2	1
60	Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3 μ g/g in Patients with Mild-to-moderate Plaque Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2012 , 5, 28-33	1.2	1
59	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , 2021 , 1	4	1
58	Comment on "PGABSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis". <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e289-e290	4.5	1
57	Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-Severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-26	2.8	1
56	Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. <i>Dermatology and Therapy</i> , 2021 , 11, 1157-1174	4	1
55	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2409-2414 ¹	4.6	1
54	The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement. <i>Journal of Dermatological Treatment</i> , 2021 , 1-3	2.8	1
53	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2398-2408	4.6	1
52	Adult-onset asymmetrical lipomatosis. <i>Cutis</i> , 2019 , 103, E4-E5	0.4	1
51	Reply to: "Comment on 'Magnesium supplementation in the treatment of pseudoxanthoma elasticum: Is magnesium oxide the best choice?'". <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, e137	4.5	0

50	Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELsus criteria: a multicenter, retrospective cohort study.. <i>British Journal of Dermatology</i> , 2022 ,	4	○
49	Durable remissions of guttate psoriasis following short courses of IL-17 inhibitors. <i>International Journal of Dermatology</i> , 2021 , 60, 1161-1162	1.7	○
48	Biosimilars in Dermatology. <i>JAMA Dermatology</i> , 2021 , 157, 641-642	5.1	○
47	The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. <i>Dermatology and Therapy</i> , 2021 , 11, 1079-1083	4	○
46	Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 1, 167-174	1.1	○
45	Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1657-1660	4.5	○
44	Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. <i>British Journal of Dermatology</i> , 2021 , 185, 840-842	4	○
43	Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics. <i>Dermatology and Therapy</i> , 2021 , 11, 1657-1665	4	○
42	Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ Years with Mild-to-Moderate Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021 , 11, 1667-1678	4	○
41	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.. <i>Dermatology and Therapy</i> , 2022 , 12, 787	4	○
40	Update on Risankizumab for Psoriasis. <i>Current Dermatology Reports</i> , 2019 , 8, 1-5	1.5	
39	SAT0559 Malignancies in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 862.2-862	2.4	
38	Annual screening for tuberculosis in patients on TNF-alfa antagonists. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, e123	4.5	
37	Miscellaneous Uses of Biologic and Systemic Agents in Other Dermatologic Conditions 2018 , 295-308		
36	A new era in the treatment of atopic dermatitis. <i>British Journal of Dermatology</i> , 2019 , 181, 658	4	
35	Update on Ustekinumab for Psoriasis. <i>Current Dermatology Reports</i> , 2017 , 6, 29-34	1.5	
34	Patient Satisfaction Scores and Standard of Care Compliance in Patients on Biologic Therapy for Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 102-105	1.1	
33	SAT0560 Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Current Status of Observations. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 862.3-863	2.4	

- 32 A Reduction in Dosage of Acitretin to 17.5 mg/day Maintains Efficacy While Improving Tolerability. *Psoriasis Forum*, **2014**, 20a, 36-48
- 31 Immunobiologics: Intermittent versus Continuous Use in the Treatment of Moderate to Severe Psoriasis. *Psoriasis Forum*, **2014**, 20a, 49-54
- 30 Biologic Drugs and Malignancy: A Literature Review Examining the Impact of Concomitant Immunosuppressive Medications. *Psoriasis Forum*, **2012**, 18a, 152-163
- 29 SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis. *Annals of the Rheumatic Diseases*, **2013**, 72, A680.2-A680 2.4
- 28 Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation. *Psoriasis Forum*, **2011**, 17a, 119-130
- 27 A randomized, double-blind, negatively controlled pilot study to determine whether the use of emollients or calcipotriol alters the sensitivity of the skin to ultraviolet radiation during phototherapy with narrowband ultraviolet B. *Yearbook of Dermatology and Dermatologic Surgery*, **2012**, 2012, 224-226
- 26 Tacalcitol : A Viewpoint by J. Baral and M. Lebwohl. *Drugs*, **1997**, 54, 272 12.1
- 25 A Practical Approach to the Use of Infliximab. *Psoriasis Forum*, **2008**, 14a, 20-22
- 24 Musculoskeletal Symptoms with Long-term Acitretin Therapy for Psoriasis: An Age- and Sex-matched Retrospective Study. *Psoriasis Forum*, **2008**, 14a, 4-7
- 23 Effects of Ultraviolet B Exposure on the Expression of Proliferating Cell Nuclear Antigen in Murine Skin. *Photochemistry and Photobiology*, **2007**, 80, 587-595 3.6
- 22 Ciclopirox 1% shampoo is a safe and effective treatment for seborrheic dermatitis. *International Journal of Dermatology*, **2004**, 43, 1-2 1.7
- 21 The cost of psoriasis treatment. *Journal of the European Academy of Dermatology and Venereology*, **2001**, 15, 290-291 4.6
- 20 Topical therapy I: corticosteroids and vitamin D analogs **2008**, 41-55
- 19 Topical Immune Response Modifiers: Adjuvants **2008**, 527-537
- 18 The Psoriasis Decision Tree. *Journal of Clinical and Aesthetic Dermatology*, **2021**, 14, 14-22 1.2
- 17 Vaccination of Patients on Biologic Agents for Psoriasis. *Psoriasis Forum*, **2005**, 11a, 7-9
- 16 Topical Immune Response Modifiers: Adjuvants **2017**, 775-790
- 15 Cutaneous Carcinogenesis Related to Dermatologic Therapy **2011**, 349-356

14	Immune gene expression in primary melanomas to predict lower risk of recurrence and death.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3014-3014	2.2
13	POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 787-788	2.4
12	Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-7	2.8
11	THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 253.1-253	2.4
10	Interleukin 12/23 Inhibitors 2021 , 302-311.e2	
9	Interleukin 17 Inhibitors 2021 , 312-320.e2	
8	Psoriasis medications: The future. <i>Dermatological Reviews</i> , 2021 , 2, 296	0.2
7	New horizons in the management of psoriasis: introduction. <i>Cutis</i> , 1998 , 61, 7	0.4
6	Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris. <i>Cutis</i> , 2007 , 79, 3-4	0.4
5	Compatibility of topical therapies for psoriasis: challenges and innovations. <i>Cutis</i> , 2007 , 79, 5-10	0.4
4	TNF-Alpha Class of Biologic Agents in Psoriatic Disease. <i>Updates in Clinical Dermatology</i> , 2022 , 25-32	0.2
3	Improving Access to Care for Patients with Psoriasis and Psoriatic Arthritis: The Impact of the Temporary Reciprocity to Ensure Access to Treatment Act and Remote Care Policy Reform. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 247553032110672	1.1
2	Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting.. <i>Dermatology and Therapy</i> , 2022 , 1	4
1	Interleukin 12/23 inhibitors 2013 , 319-332.e2	